Patrys Ltd has released a press release.
PAT-DX1 Clinical Target Indications Confirmed
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Patrys
- Patrys and WEHI Awarded Grant
- Appendix 4E and 2018 Annual Report
- Patent Granted for Pre-clinical IgM Candidate PAT-LM1
- Appendix 4C - Quarterly - 30 June 2018
- Preliminary PAT-DX1 pharmacokinetics
Later from Patrys
- Settlement of Manufacturing Claims
- Appendix 4C - Quarterly - 30 September 2018
- PAT-DX1 Suppresses Breast Cancer Brain Metastases
- Appendix 4C - Quarterly - 31 December 2018
- Appendix 4D - Half Year Accounts - 31 December 2018
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys